ClearPoint Neuro (CLPT) Competitors $11.22 -0.33 (-2.86%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLPT vs. BLFS, MDXG, ESTA, PLSE, INMD, IRMD, TNDM, KMTS, EMBC, and SIBNShould you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include BioLife Solutions (BLFS), MiMedx Group (MDXG), Establishment Labs (ESTA), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Tandem Diabetes Care (TNDM), Kestra Medical Technologies (KMTS), Embecta (EMBC), and SiBone (SIBN). These companies are all part of the "medical equipment" industry. ClearPoint Neuro vs. Its Competitors BioLife Solutions MiMedx Group Establishment Labs Pulse Biosciences InMode iRadimed Tandem Diabetes Care Kestra Medical Technologies Embecta SiBone BioLife Solutions (NASDAQ:BLFS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Which has more risk & volatility, BLFS or CLPT? BioLife Solutions has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Is BLFS or CLPT more profitable? BioLife Solutions has a net margin of -5.39% compared to ClearPoint Neuro's net margin of -66.15%. BioLife Solutions' return on equity of 0.16% beat ClearPoint Neuro's return on equity.Company Net Margins Return on Equity Return on Assets BioLife Solutions-5.39% 0.16% 0.14% ClearPoint Neuro -66.15%-94.44%-51.58% Do analysts recommend BLFS or CLPT? BioLife Solutions currently has a consensus price target of $31.29, suggesting a potential upside of 26.77%. ClearPoint Neuro has a consensus price target of $19.67, suggesting a potential upside of 75.28%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than BioLife Solutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLife Solutions 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13ClearPoint Neuro 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, BLFS or CLPT? ClearPoint Neuro has lower revenue, but higher earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLife Solutions$93.47M12.65-$20.18M-$0.12-205.67ClearPoint Neuro$31.39M10.16-$18.91M-$0.81-13.85 Does the media refer more to BLFS or CLPT? In the previous week, ClearPoint Neuro had 7 more articles in the media than BioLife Solutions. MarketBeat recorded 15 mentions for ClearPoint Neuro and 8 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.95 beat ClearPoint Neuro's score of -0.11 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of BLFS or CLPT? 93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryBioLife Solutions beats ClearPoint Neuro on 12 of the 17 factors compared between the two stocks. Get ClearPoint Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLPT vs. The Competition Export to ExcelMetricClearPoint NeuroMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$318.99M$7.02B$5.72B$9.77BDividend YieldN/A1.32%3.77%4.10%P/E Ratio-13.8527.3130.9025.26Price / Sales10.1668.25403.8188.28Price / CashN/A22.1625.2228.45Price / Book12.204.819.516.00Net Income-$18.91M$178.31M$3.26B$265.34M7 Day Performance5.85%2.41%4.48%2.84%1 Month Performance1.72%0.17%5.19%1.58%1 Year Performance4.37%9.76%31.75%25.40% ClearPoint Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLPTClearPoint Neuro1.7021 of 5 stars$11.22-2.9%$19.67+75.3%+7.4%$318.99M$31.39M-13.85110Earnings ReportAnalyst RevisionBLFSBioLife Solutions3.3868 of 5 stars$22.37-1.4%$31.29+39.9%-5.8%$1.09B$82.25M-186.40440High Trading VolumeMDXGMiMedx Group3.1983 of 5 stars$7.04+0.3%$12.00+70.5%+13.6%$1.04B$348.88M33.53870ESTAEstablishment Labs2.3085 of 5 stars$33.63-3.4%$55.80+65.9%-9.2%$1.01B$166.02M-11.031,018Analyst DowngradeHigh Trading VolumePLSEPulse Biosciences3.8233 of 5 stars$14.88+1.2%$22.00+47.8%-15.0%$989.60M$700K0.00140Earnings ReportINMDInMode2.8249 of 5 stars$13.80-2.2%$18.04+30.7%-10.3%$891.88M$394.82M5.59480News CoverageIRMDiRadimed4.5694 of 5 stars$70.00+0.1%$72.00+2.9%+57.7%$889.51M$73.24M43.21110TNDMTandem Diabetes Care4.5673 of 5 stars$10.11-10.0%$22.67+124.2%-75.8%$758.80M$940.20M-3.272,650KMTSKestra Medical Technologies1.4967 of 5 stars$14.65+0.9%$27.33+86.6%N/A$745.58M$59.81M0.00300EMBCEmbecta4.7986 of 5 stars$12.73+3.7%$19.00+49.3%-3.6%$717.67M$1.12B8.902,100Positive NewsAnalyst UpgradeGap UpHigh Trading VolumeSIBNSiBone4.3673 of 5 stars$15.40-1.8%$23.67+53.7%+11.5%$676.45M$167.18M-27.50350 Related Companies and Tools Related Companies BioLife Solutions Competitors MiMedx Group Competitors Establishment Labs Competitors Pulse Biosciences Competitors InMode Competitors iRadimed Competitors Tandem Diabetes Care Competitors Kestra Medical Technologies Competitors Embecta Competitors SiBone Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLPT) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access